Familial Hypercholesterolemia (FH) is a genetic and hereditary disorder that leads to an increased LDL (bad) cholesterol. The condition occurs at birth and can cause heart attacks at an early age.&nbsp;&nbsp;
&nbsp;
Familial Hypercholesterolemia is an autosomal-dominant disorder associated with mutations in the LDL receptor gene that increases plasma low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Patients with FH are characterized by a less LDL clearance from the circulation and a rise in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect.
&nbsp;
Familial Hypercholesterolemia Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Familial Hypercholesterolemia in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Prevalent Population of Familial Hypercholesterolemia</li>
<li>Diagnosed Prevalent Population of Familial Hypercholesterolemia</li>
<li>Mutation-specific Diagnosed Prevalence of Familial Hypercholesterolemia</li>
<li>Diagnosed Prevalence of Coronary Heart Disease due to Familial Hypercholesterolemia</li>
</ul>
&nbsp;
Familial Hypercholesterolemia Epidemiology&nbsp;
<ul>
<li>The total diagnosed prevalent population of FH in the 7MM in 2017 was 965,405</li>
<li>The diagnosed prevalent population of FH in the United States in 2017 was 244,214</li>
<li>Familial Hypercholesterolemia affects both females and males equally</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market" target="_blank" rel="noopener noreferrer">Familial Hypercholesterolemia Market</a>
The market size of Familial Hypercholesterolemia in the 7MM in 2017 was 1,069.27 USD Million
&nbsp;
Familial Hypercholesterolemia Market Drivers
<ul>
<li>Emerging potential therapies</li>
<li>Promising organizations</li>
</ul>
&nbsp;
Familial Hypercholesterolemia Market Barriers
<ul>
<li>Late diagnosis</li>
<li>Differential diagnosis</li>
<li>Lack of homozygous FH (HoFH) Awareness</li>
</ul>
&nbsp;
Familial Hypercholesterolemia Emerging Drugs
The emerging drugs of the Familial Hypercholesterolemia market are&nbsp;
<ul>
<li>Evinacumab (REGN1500)</li>
<li>Inclisiran (ALN-PCSSC)</li>
<li>LIB003 + Evolocumab</li>
<li>Gemcabene</li>
<li>Resmetirom (MGL-3196)</li>
<li>ARO-ANG3</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Familial Hypercholesterolemia Key Players
The key players in the Familial Hypercholesterolemia market are
<ul>
<li>Regeneron Pharmaceuticals</li>
<li>Novartis</li>
<li>LIB Therapeutics</li>
<li>NeuroBo Pharmaceuticals</li>
<li>Madrigal Pharmaceuticals</li>
<li>Arrowhead Pharmaceuticals</li>
</ul>
And many others.&nbsp;

Familial Hypercholesterolemia Market

Familial Hypercholesterolemia Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.